Upfront Immunotherapy for Metastatic Kidney Cancer
0 意见
• 06/26/23
0
0
嵌入
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论